MELVILLE, N.Y., May 7, 2026
BioRestorative Therapies announced expanded blinded Phase 2 clinical data for BRTX-100, its investigational autologous stem cell therapy for chronic lumbar disc disease, demonstrating sustained improvements in pain reduction and physical function through 52 weeks. The data were presented during an oral session at the International Society for Cell & Gene Therapy Annual Meeting 2026, highlighting encouraging efficacy trends and favorable safety findings as the company advances toward Phase 3 development readiness.
Expanded Phase 2 Dataset Shows Sustained Clinical Improvements
The updated blinded dataset included a significantly larger patient cohort compared to previously reported findings, with the number of evaluable patients at 52 weeks increasing from 12 to 25. According to the company, 52% of evaluable patients achieved at least 50% improvement in both pain and functional outcomes, measured using the Visual Analog Scale (VAS) and the Oswestry Disability Index (ODI). Importantly, no dose-limiting toxicities or major safety concerns related to the hypoxic-cultured mesenchymal stem cell therapy were observed.
The Phase 2 study is evaluating BRTX-100 as a potential non-surgical regenerative therapy for patients suffering from chronic lower back pain associated with degenerative disc disease. The trial’s predefined efficacy criteria include a minimum 30% reduction in pain and 30% improvement in function at 52 weeks. The newly reported data exceeded those benchmarks in a substantial percentage of patients, strengthening the therapy’s clinical profile ahead of planned topline unblinded analysis later this year.
BRTX-100 Demonstrates Strong Pain and Functional Outcomes
Advertisement
BioRestorative reported clinically meaningful improvements across multiple validated endpoints, including VAS, ODI, Functional Rating Index (FRI), and Roland-Morris Disability Questionnaire (RMDQ) scores. On the VAS pain scale, 56% of evaluable patients achieved at least 50% pain improvement at 52 weeks, with an average improvement of 71.4%. Long-term follow-up data at 104 weeks showed the average improvement increased further to 73.8%.
Functional outcomes also remained strong throughout the follow-up period. On ODI assessments, 64% of patients achieved at least 50% improvement in functional disability scores at 52 weeks, with an average improvement of 73.6%. At 104 weeks, ODI improvement remained durable at an average of 68%. Similar improvements were observed in FRI and RMDQ evaluations, where more than half of patients experienced at least 50% improvement after one year of treatment.
Company executives emphasized that chronic lumbar disc disease continues to represent a major unmet medical need, with many patients cycling through pain medications, physical therapy, injections, and invasive surgical procedures without long-term relief. BioRestorative believes BRTX-100 could emerge as a meaningful regenerative alternative designed to address the underlying degenerative process rather than only managing symptoms.
FDA Fast Track Status Supports Phase 3 Development Plans
BRTX-100 previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for chronic lumbar disc disease, a status intended to accelerate development for therapies addressing serious conditions with unmet medical needs. Earlier in 2026, the company also reported a positive Type B meeting outcome with the FDA, including alignment on key elements of the Phase 3 clinical pathway.
BioRestorative stated that Phase 3 enabling activities are currently underway, with plans to submit a Phase 3 IND application later in 2026. The company believes the consistency of the blinded Phase 2 dataset, combined with sustained long-term improvements and favorable safety observations, positions BRTX-100 as a promising candidate in the regenerative medicine and spine therapy market.
Source: BioRestorative Therapies press release
